grant
Peripheral Biomarkers for Early Diagnosis of Mixed Pathologies in AD/ADRD
Organization UNIVERSITY OF ALABAMA AT BIRMINGHAMLocation BIRMINGHAM, UNITED STATESPosted 1 Jun 2023Deadline 29 Feb 2028
NIHUS FederalResearch GrantFY2026AD and related dementiaAD dementiaAD patientsAD related dementiaADRDActive Follow-upAffectAgeAlzheimer Type DementiaAlzheimer beta-ProteinAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's Amyloid beta-ProteinAlzheimer's DiseaseAlzheimer's Disease and its related dementiasAlzheimer's amyloidAlzheimer's and related dementiasAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's diagnosisAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease and related forms of dementiaAlzheimer's disease diagnosisAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease patientAlzheimer's disease related dementiaAlzheimer's patientAlzheimers DementiaAmentiaAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid Protein A4Amyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinAssayAutopsyAβBioassayBiological AssayBiological MarkersBiopsyBiopsy SampleBiopsy SpecimenBrainBrain Nervous SystemBrain imagingCadaverClinicClinicalCollectionConsensusCorticodentatonigral degeneration with neuronal achromasiaDLBDementiaDementia with Lewy BodiesDepositDepositionDermatologic biopsyDetectionDevelopmentDiagnosisDiagnostic testsDifferential DiagnosisDiseaseDisease ProgressionDisorderEarly DiagnosisEmergent TechnologiesEmerging TechnologiesEncephalonGoalsImmunoassayLB dementiaLewy Body DementiaLewy Body Type Senile DementiaLewy dementiaMT-bound tauMeasuresMemoryNAC precursorOutcomeOutcome StudyPARK1 proteinPARK4 proteinPD dementiaPD with dementiaParalysis AgitansParkinsonParkinson DiseaseParkinson Disease dementiaParkinson's DementiaParkinson's disease with dementiaParticipantPathologicPathologyPatient CarePatient Care DeliveryPatientsPeripheralPersonsPositionPositioning AttributePrimary ParkinsonismPrimary Senile Degenerative DementiaProbabilityProgressive Supranuclear OphthalmoplegiaProgressive Supranuclear PalsyRegistriesResearchResearch ResourcesResearch SpecimenResourcesSNCASNCA proteinSamplingSeverity of illnessSkinSpecimenSteele-Richardson-Olszewski DiseaseSteele-Richardson-Olszewski SyndromeSymptomsTau forming aggregatesTauopathiesTestingTimeValidationVisita beta peptidea-syna-synucleinaberrant tauaberrant tau proteinabetaabnormal tauabnormal tau proteinabnormally aggregated tau proteinaccurate diagnosisactive followupagesaggregation in taualpha synucleinalpha synuclein genealphaSP22amyloid betaamyloid-b proteinasynbeta amyloid fibrilbio-markersbiobankbiologic markerbiomarkerbiorepositorybrain tissuebrain visualizationcadavericcadaverscare for patientscare of patientscaring for patientsclinical diagnosisclinical practiceco-morbidco-morbiditycomorbiditycortical basal degenerationcortico-basal syndromecorticobasal degenerationcorticobasal syndromecutaneous biopsydementia due to Parkinson diseasedementia in PDdementia in Parkinson diseasedevelopmentaldiagnostic assaydiagnostic biomarkerdiagnostic markerdiagnostic tooldisease durationdisease lengthdisease severityearly biomarkersearly detectionearly detection biomarkersearly detection markersfilamentous tau inclusionfollow upfollow-upfollowed upfollowupillness lengthimprovedmicrotubule associated protein tau aggregationmicrotubule associated protein tau depositmicrotubule associated protein tau mutationmicrotubule bound taumicrotubule-associated protein tau mutationmicrotubule-bound taumutant taumutant tau proteinmutation in microtubule associated protein taumutation in microtubule-associated protein taunecropsyneuropathologicneuropathologic tauneuropathologicalneuropathological tauneuropathologynew markernew technologynon A-beta component of AD amyloidnon A4 component of amyloid precursornovel biomarkernovel markernovel technologiesp-taup-τpaired helical filament of taupathogenic taupathogenic tau gene mutationpathogenic tau proteinpathological change in taupathological taupathological tau proteinpatient living with Alzheimer's diseasepatient suffering from Alzheimer's diseasepatient with Alzheimer'spatient with Alzheimer's diseasepatients with ADphospho-tauphospho-τphosphorylated taupost-translational modification of taupostmortemposttranslational modification of tauprimary degenerative dementiaprion-likeprospectiverecruitself-aggregate tausenile dementia of the Alzheimer typesexskin biopsysoluble amyloid precursor proteinsuccesssynucleinopathytautau PHFtau Proteinstau abnormalitytau accumulationtau aggregatetau aggregationtau associated neurodegenerationtau associated neurodegenerative processtau driven neurodegenerationtau factortau fibrillationtau fibrillizationtau filamenttau inclusiontau induced degenerationtau induced neurodegenerationtau intronic mutationtau mediated neurodegenerationtau mutationtau neurodegenerative diseasetau neurofibrillary tangletau neuropathologytau oligomertau paired helical filamenttau pathological changetau pathologytau pathophysiologytau phosphorylationtau polymerizationtau posttranslational modificationtau protein accumulationtau protein aggregationtau proteinopathytau related neurodegenerationtau-1tau-induced pathologytau-tau interactiontauopathic neurodegenerative disordertauopathytherapeutic agent developmenttherapeutic developmentvalidationsα synuclein geneα-synα-synucleinτ Proteinsτ aggregationτ mutationτ phosphorylation
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
The overall goal of our proposed research is to develop robust premortem biomarkers for accurate and
differential diagnosis of Alzheimer's disease (AD), non-AD tauopathies, Lewy body dementia (LBD), and their
comorbidities. A pathological hallmark of AD and other tauopathies is the deposition of tau protein aggregates
in the brain, whereas in LBD…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click